(1) The approval of Ziihera, which previously received Breakthrough Therapy Designation from the FDA for this indication, is an important advance and offers the first and only dual HER2-targeted ...
And, pending approval, Zymeworks is eligible to receive tiered royalties between 10% and 20% on Jazz’s net sales. Zanidatamab is an HER2-targeted bispecific antibody with multiple novel ...
Jazz Pharmaceuticals (NASDAQ:JAZZ) and Zymeworks (NASDAQ:ZYME) announced Thursday the FDA approval of their jointly developed bispecific antibody Ziihera as a late-line treatment for certain adults ...
is an important advance and offers the first and only dual HER2-targeted bispecific antibody and chemotherapy-free treatment for patients living with BTC. In late 2022, Zymeworks entered into a ...
Ziihera is one of several variations of the bispecific antibody Zanidatamab that Zymeworks developed for treating various types of cancer, and one of three in the advanced “pivotal” trial phase.
Zymeworks Inc is a clinical-stage biopharmaceutical ... Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase ...
This event, led by Paul Moore, PhD, Zymeworks’ Chief Scientific Officer, will feature: Updates on our portfolio of solid tumor targeting antibody-drug conjugates and T-cell Engager (TCE ...